Identifying the Profile of Helicobacter pylori-Negative Gastric Cancers: A Case-Only Analysis within the Stomach Cancer Pooling (StoP) Project

Autores da FMUP
Participantes de fora da FMUP
- Morais, S
- Peleteiro, B.
- Ara?jo, N.
- Malekzadeh, R
- Ye, WM
- Plymoth, A
- Tsugane, S
- Hidaka, A
- Hamada, GS
- Lopez Carrillo, L
- Zaridze, D
- Maximovich, D
- Aragones, N
- Castano Vinyals, G
- Pakseresht, M
- Hernandez Ramirez, RU
- Lopez Cervantes, M
- Leja, M
- Gasenko, E
- Pourfarzi, F
- Zhang, ZF
- Yu, GP
- Derakhshan, MH
- Pelucchi, C
- Negri, E
- La Vecchia, C
Unidades de investigação
Abstract
Background: The prevalence of Helicobacter pylori-negative gastric cancer (HpNGC) can be as low as 1%, when infection is assessed using more sensitive tests or considering the presence of gastric atrophy. HpNGC may share a high-risk profile contributing to the occurrence of cancer in the absence of infection. We estimated the proportion of HpNGC, using different criteria to define infection status, and compared HpNGC and positive cases regarding gastric cancer risk factors. Methods: Cases from 12 studies from the Stomach cancer Pooling (StoP) Project providing data on H. pylori infection status determined by serologic test were included. HpNGC was reclassified as positive (eight studies) when cases presented CagA markers (four studies), gastric atrophy (six studies), or advanced stage at diagnosis (three studies), and were compared with positive cases. A two-stage approach (random-effects models) was used to pool study-specific prevalence and adjusted odds ratios (OR). Results: Among non-cardia cases, the pooled prevalence of HpNGC was 22.4% (n = 166/853) and decreased to 7.0% (n = 55) when considering CagA status; estimates for all criteria were 21.8% (n = 276/1,325) and 6.6% (n = 97), respectively. HpNGC had a family history of gastric cancer more often [OR = 2.18; 95% confidence interval (CI), 1.03-4.61] and were current smokers (OR = 2.16; 95% CI, 0.52-9.02). Conclusion: This study found a low prevalence of HpNGC, who are more likely to have a family history of gastric cancer in first-degree relatives. Impact: Our results support that H. pylori infection is present in most non-cardia gastric cancers, and suggest that HpNGC may have distinct patterns of exposure to other risk factors.
Dados da publicação
- ISSN/ISSNe:
- 1055-9965, 1538-7755
- Tipo:
- Article
- Páginas:
- 200-209
- Link para outro recurso:
- www.scopus.com
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION American Association for Cancer Research Inc.
Citações Recebidas na Web of Science: 5
Citações Recebidas na Scopus: 8
Documentos
- Não há documentos
Filiações
Filiações não disponíveis
Keywords
- RISK-FACTORS; SOCIOECONOMIC POSITION; JAPANESE BRAZILIANS; TOBACCO SMOKING; POOLED ANALYSES; PUBLISHED DATA; INFECTION; CARCINOGENESIS; METAANALYSES; CONSUMPTION
Campos de estudo
Proyectos asociados
Healthcare use among cancer patients and their partners in different phases of the cancer pathway
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2021
Reshaping organized cervical cancer screening: strategies to increase the adherence and reduce invitation costs
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2020
Using pooled analyses based on individual participant data for a finer assessment of gastric cancer etiology
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2020
RISK AND SURVIVAL OF GASTRIC CANCER RELATES SECOND PRIMARY TUMOURS: A COMPETING RISKS FRAMEWORK
Investigador Principal: Nuno Miguel de Sousa Lunet
Estudo Clínico Académico . 2019
Citar a publicação
Morais S,Peleteiro B,Ara?jo N,Malekzadeh R,Ye WM,Plymoth A,Tsugane S,Hidaka A,Hamada GS,Lopez L,Zaridze D,Maximovich D,Aragones N,Castano G,Pakseresht M,Hernandez RU,Lopez M,Leja M,Gasenko E,Pourfarzi F,Zhang ZF,Yu GP,Derakhshan MH,Pelucchi C,Negri E,La Vecchia C,Lunet N. Identifying the Profile of Helicobacter pylori-Negative Gastric Cancers: A Case-Only Analysis within the Stomach Cancer Pooling (StoP) Project. Cancer Epidemiol. Biomarkers Prev. 2022. 31. (1):p. 200-209. IF:3,800. (2).